Next-generation dendritic cell–based vaccines [WEBINAR]

For more information visit https://www.miltenyibiotec.com/applic... This webinar explains how to tackle challenges in next-generation DC manufacturing: We focus on enrichment of primary DC subsets from peripheral blood and increasing manufacturing sustainability with the CliniMACS Prodigy® Platform.

In the last decade, several DC-based vaccination and other pioneering immunotherapeutic treatments have paved the way to a new personalized approach to cancer treatment. DC–based vaccination aims to enhance the immune system’s ability to attack the tumor. However, limitations like low efficacy and low sustainability of the manufacturing process are still a challenge for DC-based therapies. Watch the webinar recording and learn how enrichment of primary dendritic cell (DC) subsets and sustainable DC manufacturing advances DC-based cell therapies.

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.